United Therapeutics Corporation $UTHR Shares Sold by Tower View Wealth Management LLC

Key Points

• Tower View Wealth Management cut its United Therapeutics stake by 96.8% in the third quarter, selling 2,911 shares and retaining just 95 shares worth approximately $51,000. Institutional investors collectively own 94.08% of the company.
• Analysts remain broadly positive: United Therapeutics has a “Moderate Buy” consensus rating, with an average price target of $650.43 versus a recent share price of $587.50. Price targets range as high as $725, though some analysts maintain neutral ratings.
• The company authorized a $2 billion share-repurchase program, allowing it to buy back up to 8.3% of outstanding shares. United Therapeutics also reported quarterly EPS of $7.27, beating estimates, while revenue declined 1.9% year over year.

Tower View Wealth Management LLC reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 96.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95 shares of the biotechnology company's stock after selling 2,911 shares during the quarter. Tower View Wealth Management LLC's holdings in United Therapeutics were worth $51,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Callan Family Office LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth $1,217,000. Andra AP fonden lifted its position in shares of United Therapeutics by 33.5% during the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company's stock valued at $18,912,000 after purchasing an additional 8,760 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of United Therapeutics during the second quarter valued at about $3,359,000. Partners Capital Investment Group LLP bought a new position in shares of United Therapeutics during the second quarter valued at about $1,691,000. Finally, Hsbc Holdings PLC boosted its holdings in United Therapeutics by 6.6% during the second quarter. Hsbc Holdings PLC now owns 127,125 shares of the biotechnology company's stock worth $68,899,000 after purchasing an additional 7,890 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. UBS Group set a $725.00 price objective on United Therapeutics in a research note on Monday, October 19th. Morgan Stanley upped their price objective on United Therapeutics from $515.00 to $566.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 7th. Raymond James Financial reiterated an "outperform" rating and set a $717.00 target price on shares of United Therapeutics in a research note on Tuesday, October 20th. Finally, Leerink Partners boosted their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an "outperform" rating in a report on Monday, October 19th. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $650.43.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $587.50 on Monday. The stock has a fifty day simple moving average of $519.14 and a two-hundred day simple moving average of $539.93. United Therapeutics Corporation has a 1-year low of $409.07 and a 1-year high of $609.35. The firm has a market cap of $25.20 billion, a price-to-earnings ratio of 21.02, a price-to-earnings-growth ratio of 4.26 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.41 earnings per share. Analysts forecast that United Therapeutics Corporation will post 26.07 EPS for the current year.

United Therapeutics declared that its Board of Directors has authorized a share repurchase program on Thursday, October 22nd that allows the company to buy back $2.00 billion in shares. This repurchase authorization allows the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's management believes its shares are undervalued.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: $2 billion buyback authorization: United Therapeutics’ board approved an additional $2 billion share-repurchase program, potentially covering up to 8.3% of outstanding shares. The authorization could reduce the share count, support future earnings per share and signal that management considers the stock undervalued. United Therapeutics Authorizes Additional $2 Billion Share Buyback Program
• Positive Sentiment: Analyst targets remain above the current share price: Recent research includes bullish ratings and targets as high as $725. The broader analyst consensus remains “Moderate Buy,” with an average target of approximately $650, although ratings are not unanimous. Analysts Conflicted on United Therapeutics
• Neutral Sentiment: CEO sold a relatively small portion of holdings: CEO Martine Rothblatt sold 9,500 shares for about $5.3 million, reducing her direct ownership by 2.84%. She still owns more than 324,000 shares, so the transaction may represent personal diversification rather than a change in business outlook. SEC Insider Trading Filing
• Negative Sentiment: Tyvaso faces near-term pressure: RBC warned that United Therapeutics’ settlement with Liquidia could weigh on the outlook for Tyvaso, raising concerns about competition and growth for the company’s key pulmonary arterial hypertension franchise. United Therapeutics Tyvaso Outlook Faces Near-Term Pressure

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $167,432,054.58. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 392,028 shares of company stock valued at $203,299,671 in the last three months. 8.60% of the stock is currently owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.